G. Gordon McHardy, M.D., F.A.C.P.; Claude C. Craighead, M.D.; Louis Balart, M.D.; Robert J. McHardy, M.D. (Associate); Clinton La Grange, B.S.; Donald Bradburn, M.D.; Harold Cradic, B.S.
This content is PDF only. Please click on the PDF icon to access.
The pathogenesis of pancreatitis is not clearly defined. Therapeutic limitation and a high case fatality rate warrant reevaluation of experimentally induced pancreatitis as modified by a trypsin inhibitor in an effort to establish its possible specificity in the management of pancreatitis in humans.
The first objective was the confirmatory reproduction of acute pancreatitis, creating intrapancreatic proteolytic trypsin activity in mongrel dogs.
The second objective was an evaluation of a trypsin and kallikrein inhibitor as a protection against such experimentally produced pancreatitis. The trypsin inhibitor used was that isolated from the parotid gland of cattle with in vitro potency of 1:4
McHardy GG, Craighead CC, Balart L, McHardy RJ, Grange CL, Bradburn D, et al. Pancreatitis: An Evaluation of a Trypsin Inhibitor.. Ann Intern Med. ;60:325–326. doi: 10.7326/0003-4819-60-2-325_3
Download citation file:
Published: Ann Intern Med. 1964;60(2_Part_1):325-326.
Gastroenterology/Hepatology, Pancreatic Disease.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use